| P50 | author | Elizabeth J Shpall | Q87373605 |
| | Stephen Spellman | Q111077182 |
| | John C. Burnett | Q50421173 |
| P2093 | author name string | John J Rossi | |
| | Loren Gragert | |
| | Joanne Kurtzberg | |
| | Pamela Clark | |
| | Sue Armitage | |
| | Shirley Li | |
| | Haitang Li | |
| | Jonathan A Gutman | |
| | Sergio Querol | |
| | Lawrence D Petz | |
| | Richard Tonai | |
| | Donna M Regan | |
| | Milena Bakalinskaya | |
| P2860 | cites work | Foamy virus vectors for HIV gene therapy | Q26859020 |
| | More on shift of HIV tropism in stem-cell transplantation with CCR5 delta32/delta32 mutation. | Q51074921 |
| | A phase I trial of autologous CD34+ hematopoietic progenitor cells transduced with an anti-HIV ribozyme | Q73022564 |
| | Haplo-cord transplantation using CD34+ cells from a third-party donor to speed engraftment in high-risk patients with hematologic disorders | Q85637058 |
| | Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells | Q37401812 |
| | Alternative haematopoietic stem cell sources for transplantation: place of umbilical cord blood | Q37435417 |
| | CCR5 as a natural and modulated target for inhibition of HIV. | Q37566693 |
| | Current status and challenges of antiretroviral research and therapy | Q37657867 |
| | Genetic modification of hematopoietic stem cells as a therapy for HIV/AIDS. | Q37666741 |
| | Alternative donor transplantation--"mixing and matching": the role of combined cord blood and haplo-identical donor transplantation (haplo-cord SCT) as a treatment strategy for patients lacking standard donors? | Q38350274 |
| | Short communication: Efficiently inhibiting HIV-1 replication by a prototype foamy virus vector expressing novel H1 promoter-driven short hairpin RNAs | Q38926383 |
| | CCR5 Δ32 homozygous cord blood allogeneic transplantation in a patient with HIV: a case report | Q38978741 |
| | Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor | Q39600778 |
| | Stable human immunodeficiency virus type 1 (HIV-1) resistance in transformed CD4+ monocytic cells treated with multitargeting HIV-1 antisense sequences incorporated into U1 snRNA. | Q39879519 |
| | Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure | Q41212897 |
| | Safety and efficacy of a tCD25 preselective combination anti-HIV lentiviral vector in human hematopoietic stem and progenitor cells | Q41591165 |
| | Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation | Q43806342 |
| | Single cord blood combined with HLA-mismatched third party donor cells: comparable results to matched unrelated donor transplantation in high-risk patients with hematologic disorders | Q43978870 |
| | Immune reconstitution after combined haploidentical and umbilical cord blood transplant | Q45142789 |
| | A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children. | Q45748774 |
| | Analysis of CCR5-Delta 32 and CCR2-V64I polymorphisms in a cohort of Spanish HCV patients using real-time polymerase chain reaction and fluorescence resonance energy transfer technologies | Q47257043 |
| | HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry | Q50109403 |
| | Lentivirus-mediated Gene Transfer in Hematopoietic Stem Cells Is Impaired in SHIV-infected, ART-treated Nonhuman Primates | Q27318042 |
| | Understanding HIV latency: the road to an HIV cure | Q28085296 |
| | Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV | Q28235281 |
| | Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease | Q28284509 |
| | Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1 | Q28290118 |
| | CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection | Q28542878 |
| | Development of Hematopoietic Stem Cell Based Gene Therapy for HIV-1 Infection: Considerations for Proof of Concept Studies and Translation to Standard Medical Practice | Q29036869 |
| | Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection | Q29614956 |
| | Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation | Q29615068 |
| | Identification and frequency of CCR5Δ32/Δ32 HIV-resistant cord blood units from Houston area hospitals. | Q33615123 |
| | TALENs facilitate targeted genome editing in human cells with high specificity and low cytotoxicity | Q33698693 |
| | Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Δ32 mutation confers resistance to HIV infection | Q33854184 |
| | Ribozyme therapy for HIV infection | Q34062644 |
| | RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma | Q34121209 |
| | Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo | Q34124290 |
| | A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. | Q34205743 |
| | Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5 | Q34325074 |
| | Global distribution of the CCR5 gene 32-basepair deletion. | Q34425080 |
| | Towards an HIV cure: a global scientific strategy | Q34640562 |
| | HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells | Q34672568 |
| | Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9 | Q34727851 |
| | Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors | Q35064224 |
| | Foamy combinatorial anti-HIV vectors with MGMTP140K potently inhibit HIV-1 and SHIV replication and mediate selection in vivo | Q35182775 |
| | Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations | Q35521811 |
| | Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions | Q35608181 |
| | Precision genome engineering with programmable DNA-nicking enzymes | Q36093894 |
| | Hematopoietic cell transplantation with cord blood for cure of HIV infections | Q36295174 |
| | Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation | Q36409885 |
| | Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV | Q36654098 |
| | Umbilical cord blood transplantation supported by third-party donor cells: rationale, results, and applications | Q36746512 |
| | HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression | Q36781531 |
| | Stable gene transfer of CCR5 and CXCR4 siRNAs by sleeping beauty transposon system to confer HIV-1 resistance | Q36870325 |
| | Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases | Q36915157 |
| | Preclinical in vivo evaluation of the safety of a multi-shRNA-based gene therapy against HIV-1 | Q37256335 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell biology | Q7141 |
| P304 | page(s) | 109-116 | |
| P577 | publication date | 2015-07-28 | |
| P1433 | published in | Stem Cells and Cloning: advances and applications | Q15817523 |
| P1476 | title | Progress toward curing HIV infection with hematopoietic cell transplantation | |
| P478 | volume | 8 | |